Company / R&D per Share
Ultragenyx Pharmaceutical Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$8.11
FY2025
5-year range
$5.35 / $10.18
FY2021-FY2025
Trend
-4.4%
vs FY2024
Sector context
#22 of 208
Health Care
What the data says
Ultragenyx Pharmaceutical Inc.'s r&d per share of $8.11 is higher than 89% of companies in the Health Care sector (FY2025). R&D per Share has declined for 3 consecutive years, from $10.18 in FY2022 to $8.11 in FY2025.
Based on SEC 10-K filings.
8.11 in FY2025 with a 5-year CAGR of +9.8%. Top quartile in the Health Care sector.
Declined from $9.23 to $8.11 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -7.3%
- 5-Year CAGR
- +9.8%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 208This company $8.11 Sector average $28.82
▼
-71.9% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 4.4% year-over-year.
- Ranks #22 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.11 | -4.4% |
| FY2024 | $8.48 | -8.1% |
| FY2023 | $9.23 | -9.3% |
| FY2022 | $10.18 | +90.3% |
| FY2021 | $5.35 | +5.2% |
| FY2020 | $5.08 | +11.6% |
| FY2019 | $4.55 | -31.6% |
| FY2018 | $6.66 | +139.3% |
| FY2017 | $2.78 | +135.3% |
| FY2016 | $1.18 | -62.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026